💊
Ahzantive
aflibercept
Wet Macular Degeneration;Macular Edema;Retinal Vein Occlusion;Choroidal Neovascularization;Diabetes Complications
✅ Authorised
Biosimilar
✅
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Ahzantive is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), • visual impairment due to diabetic macular oedema (DME) (see section 5.1), • visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).
⚠️ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/ahzantive